|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
High Blood Pressure
Also known as hypertension (hi-per-TEN-shun), this condition usually causes no symptoms, unless the pressure gets extremely high; it's therefore often called the "silent killer". Over time the elevated pressure causes damage to the blood vessels and to the organs the vessels supply with blood. This can result in stroke, heart attack, kidney failure, heart failure and damage to the eye, called retinopathy.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Hypertension (w/Diabetes) Study - AUS02
An 8 week randomized, double-blind, parallel group, multi-center, active controlled study to evaluate the antihypertensive efficacy and safety of a Novartis investigational drug in hypertensive people with Type 2 diabetes mellitus. An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.
Trial phase: Phase 4 Participation Duration: Participants will be required to visit the study center between 5 to 8 times over a duration of 9 to 12 weeks. Protocol Number: CSPV100AUS02 Hypertension Study (ages 6-17) - A2365
A multicenter, randomized, double-blind, 8 week study to evaluate the dose response, efficacy and safety of a Novartis investigational drug in pediatric hypertensive participants between 6-17 years of age. “An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA). This investigational drug may not become commercially available.
Trial phase: Phase 3 Participation Duration: This study has 3 parts and will last from 60 to 78 days. Participants will be asked to visit the doctors office/clinic/site 6 times. Each visit should take about 45 minutes. Protocol Number: CSPP100A2365 |